RxDoctor Payments Data

Cody Harris

Family · Lewiston, IDNPI 1992081467

Payments from drug & device makers

$1,981in general payments, 2019–2025

Across 126 payments — averaging $15.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$503
  • GSK$436
  • Pfizer$348
  • AstraZeneca$313
  • Abbott$69
  • Novartis$66
  • plus $247 from 9 others

What the payments were for

  • Food & beverage$1,96799%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,981 in reported general payments places this provider in the 85th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Medicare billing

Part B allowed, 2024
$94,865
Medicare patients
319
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$70,905
OzempicSemaglutide71$67,750
JanuviaSitagliptin Phosphate23$18,378
MyrbetriqMirabegron14$17,347
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$12,282
Combivent RespimatIpratropium/Albuterol Sulfate22$11,351
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen159$5,933
Sumatriptan Succinate22$3,288
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$2,956
Potassium Chloride138$2,939
Albuterol Sulfate HfaAlbuterol Sulfate89$2,769
Levothyroxine Sodium230$2,504
Pregabalin63$2,287
Ventolin HfaAlbuterol Sulfate30$2,043
Tamsulosin Hcl133$1,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$348$70,90593 claims
Novo NordiskOzempic$36$67,75071 claims
AstraZenecaBreztri Aerosphere$313$12,28218 claims
AbbVieSynthroid$503$89813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 809 family providers in Idaho.

Other family in Lewiston

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →